← Back to all trials
Active Not Recruiting
NCT04590235
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
Conditions: Neurofibromatosis 1, Neurofibroma Plexiform
Sex: All
Ages: 3 Years – 99 Years
Healthy volunteers: No
Phase: PHASE1
Enrollment: 32
Sponsor: AstraZeneca
Location: Research Site Shanghai
Summary
A Phase 1 Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of Selumetinib, a Selective Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor, in Chinese Paediatric and Adult Subjects with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN).
Eligibility Criteria
Inclusion Criteria:
* Paediatric cohort: Chinese subjects ≥3 years and \
Source: ClinicalTrials.gov (NCT04590235). StuddyBuddy aggregates publicly available trial information.
